Core Insights - Treatment.com AI Inc. has launched the Healthy Aging Program, a pilot initiative offering free virtual health screenings for adults aged 60 and older in New York City, funded by a $1 million grant from the CVS Health Foundation [1][2][3] Group 1: Program Details - The Healthy Aging Program provides confidential virtual assessments for common health concerns related to aging, including heart health, memory, and mental well-being, conducted by board-certified physicians [2][4] - Participants completing screenings receive health information, a physician consultation, and may earn up to $45 in gift cards, with no insurance required for Medicaid patients and coverage for Medicare patients [3][7] - The program aims to support older adults in maintaining health and independence, addressing barriers such as language and digital literacy [4][7] Group 2: Organizational Background - Rocket Doctor Inc. is a technology-driven digital health platform that enables doctors to manage virtual practices, focusing on underserved communities [5] - EngageWell IPA, established in 2016, aims to provide coordinated healthcare options addressing social determinants of health, striving for a more equitable healthcare system [7][8] - Treatment.com AI utilizes AI to improve healthcare efficiency, offering a comprehensive healthcare AI engine known as the Global Library of Medicine, which supports healthcare professionals [9]

Group 1 - The Russell 2000 index is experiencing significant growth, approaching new all-time highs, with the iShares Russell 2000 ETF IWM up over 25% from its lows on April 8 [1] - Small-cap companies like Oklo Inc, NuScale Power Corp, and Hims & Hers Health Inc are showing remarkable year-to-date gains of 159%, 107%, and 95% respectively, defying broader market concerns [2][3] - These companies are benefiting from strong secular trends that appear to be resistant to tariff impacts, despite the potential for increased volatility in multinational operations due to trade rhetoric [3] Group 2 - Oklo Inc has seen a year-to-date surge of over 159%, driven by investor interest in next-generation clean energy technologies, particularly small modular reactors [4] - NuScale Power has rebounded significantly, with shares doubling in 2025 on renewed interest in small modular reactors and a boost from NRC approval, despite potential tariff impacts on construction costs [5] - Hims & Hers Health Inc is capitalizing on recession fears, achieving 95% year-to-date gains through its asset-light model and strong customer retention, which have shielded it from macroeconomic shocks [6] Group 3 - The performance of these small-cap companies indicates that certain segments of the market are thriving, even as larger companies face challenges from macroeconomic headlines and tariff concerns [7]

Innovative initiative combines QHSLab’s digital platform with on-site behavioral health services to advance timely, effective care. MIAMI, FL, July 08, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, announced today the opening of its first co-branded QHS Behavioral Healthcare Center (QBHC) in Miami. First unveiled in a letter to shar ...

Core Insights - Treatment.com AI Inc. has successfully completed the acquisition of Rocket Doctor, enhancing its mission to integrate AI with virtual healthcare delivery [2][9] - The acquisition has led to significant growth in patient volume and physician adoption for Rocket Doctor, indicating strong market demand [3][9] Company Achievements - Rocket Doctor reported a 112% year-over-year increase in patient volume in Alberta, with 36,779 patients seen in the past year [3][9] - The platform has served over 71,000 Albertans, with 35% of patients from communities with populations under 25,000, highlighting its role in underserved areas [3] - Physician adoption increased by 218%, from 22 active physicians last year to 70 this year, allowing for rapid scaling [3] Product Development - Treatment.com AI launched a new generation of the Medical Education Suite (MES) at the University of Minnesota Medical School, featuring AI-simulated patients for assessing third-year medical students [4] - The MES has the potential to reduce exam administration costs by approximately 40% and decrease faculty workload [4] Partnerships and Collaborations - Rocket Doctor initiated a virtual care program in California with Central California Alliance for Health, serving around 450,000 members [5] - In Canada, Rocket Doctor partnered with Melanoma Canada to enhance follow-up care for high-risk skin cancer patients in Ontario, Alberta, and British Columbia [6] Recognition and Awards - Rocket Doctor was named Top Clinical Innovator by the American Telemedicine Association at the NEXUS2025 conference, recognizing its physician-led virtual care model [7][9] - The company has been invited to participate in prestigious accelerators and thought leadership programs, including the UC Berkeley Health Engine Accelerator and AARP's AgeTech Accelerator [8][9] Leadership and Insights - Dr. William Cherniak, CEO of Rocket Doctor, emphasized the transformational period for both companies, focusing on a shared vision and execution across various healthcare fronts [12] - A peer-reviewed research paper co-authored by Dr. Cherniak and other physicians provides insights into patient behavior and the role of digital tools in enhancing health equity [11]

Core Insights - iRhythm Technologies, Inc. announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025, and appointed Karen McGinnis and Kevin O'Boyle to the board of directors [1][2][4] Group 1: Board Member Changes - Mark Rubash served on the board since 2016, contributing extensive experience in finance, accounting, and strategy [2] - Ralph Snyderman, M.D., joined the board in 2017, providing clinical expertise and guidance during early digital technology challenges [2] - The new board members, Karen McGinnis and Kevin O'Boyle, bring significant financial and operational experience from the medical and biotechnology sectors [3][4] Group 2: New Board Members' Background - Karen McGinnis has over 30 years of experience in leading international companies across various industries, including biotechnology and technology, and previously served as Chief Accounting Officer at Illumina, Inc. [5][6] - Kevin O'Boyle has over 20 years of executive leadership experience, notably as CFO at NuVasive, where he significantly increased the company's market capitalization [9][10] Group 3: Company Vision and Strategy - iRhythm Technologies focuses on creating solutions that detect, predict, and prevent disease through wearable biosensors and cloud-based data analytics [12] - The company aims to deliver better data, insights, and health outcomes for patients globally [12]

Core Insights - OptimizeRx (OPRX) started 2025 with strong momentum, achieving 11% year-over-year revenue growth to $21.9 million and $1.5 million in adjusted EBITDA, marking its best first-quarter performance to date [1] - The company raised its full-year revenue guidance to $101-$106 million, expecting adjusted EBITDA between $13-$15 million, with over 80% of the revenue guidance coming from existing contracts [2] - A strategic shift towards a subscription-based revenue model is underway, with early adoption exceeding 5% of projected revenues, aimed at smoothing revenue flows and enhancing margins [2] Financial Performance - OPRX's gross margins decreased slightly to 60.9% from 62% the previous year, attributed to a higher mix of lower-margin DTC managed services [3] - The company reported a stronger operating cash flow of $3.9 million, supporting a cash balance of $16.6 million [1] Market Position and Strategy - Pharma clients are increasingly focused on efficiency and ROI in their marketing budgets, aligning with OptimizeRx's omnichannel platform that integrates point-of-care and real-world patient targeting [4] - Early results from the platform indicate a script lift of 25% and a 10:1 ROI, reinforcing its value proposition [4] - OPRX is navigating macro uncertainty effectively, benefiting from committed revenues, cost efficiencies, and a pivot to subscriptions [5] Peer Comparison - Veeva Systems (VEEV) reported $759 million in revenues for the first quarter of fiscal 2026, up 16.7% year-over-year, driven by strong adoption of its products [6] - Health Catalyst (HCAT) achieved $79.4 million in first-quarter revenue, up 6.3% year-over-year, with its Ignite platform driving 10% growth [7] Stock Performance and Valuation - OPRX shares have surged 176.4% year-to-date, significantly outperforming the industry growth of 15% [8] - The forward 12-month price-to-sales ratio for OPRX is 2.25X, lower than the industry average of 8.67X and its five-year median of 3.63X [11] - The Zacks Consensus Estimate for OPRX's 2025 earnings per share suggests a 63.6% improvement from 2024 [12]

Core Insights - Hims & Hers Health, Inc. (HIMS) is leveraging artificial intelligence (AI) to transform healthcare delivery, aiming for a more personalized, scalable, and accessible approach [1][6] - The company appointed Mo Elshenawy as CTO to lead AI integration, focusing on creating an AI-powered healthcare platform that enhances diagnosis, treatment, and delivery [1][6] - Hims & Hers raised $870 million in convertible notes to fund AI tools and expand personalized treatment options, reflecting its commitment to modernizing healthcare infrastructure [2][6] AI Integration and Innovations - Hims & Hers is developing an AI-driven healthcare platform that includes initiatives like the intelligent MedMatch routing system to improve diagnostic accuracy and patient experience [2] - Teladoc Health, Inc. (TDOC) is also utilizing AI to enhance its virtual care ecosystem, focusing on intelligent triage and predictive analytics to improve patient outcomes [3] - Tempus AI, Inc. (TEM) is embedding AI in precision medicine, particularly in oncology and neurogenomics, to optimize clinical workflows and support real-time clinical decision-making [4] Financial Performance and Estimates - Hims & Hers shares have increased by 95.7% year-to-date, significantly outperforming the industry growth of 19.7% [5] - The Zacks Consensus Estimate predicts a 174.1% improvement in HIMS' earnings per share from 2024 to 2025 [7] - HIMS' forward 12-month price-to-sales ratio is 4.1X, lower than the industry average of 5.8X but higher than its three-year median of 2.3X [9]

Core Insights - OptimizeRx (OPRX) has reported strong first-quarter results for fiscal 2025, exceeding Wall Street expectations and reflecting positively in its share price performance over the past three months [1][4]. Financial Performance - Revenue increased by 11% year over year to $21.9 million, with a positive operating cash flow of $3.9 million, marking a significant turnaround from the previous year [2][10]. - Contracted revenues grew by 25% year over year, now exceeding $70 million, which accounts for over 80% of the midpoint of the FY25 revenue guidance [9][11]. - Gross margins remained steady at 60.9%, while operating expenses declined due to reduced stock-based compensation and cost controls [7][10]. Market Position and Growth - OPRX's shares surged by 69.3% in the past three months, significantly outperforming the broader industry growth of 36.7% and the S&P 500's gain of 22.1% during the same period [4][5]. - The company is transitioning to a subscription-based revenue model, with over 5% of projected 2025 revenues already tied to recurring contracts, particularly in its DAAP and Medicx data businesses [12][10]. Valuation - OPRX is attractively priced, trading at a forward price-to-sales (P/S) ratio of 2.2X, well below its five-year median of 3.64X and the industry average of 8.64X [13]. Strategic Outlook - Management has raised its full-year guidance and reaffirmed its ambition to achieve Rule of 40 metrics, indicating a combined annual revenue growth rate and EBITDA margin of 40% or higher within the next several years [2][10]. - The company is focused on deepening client relationships and scaling its omnichannel platform, which is expected to create sustained shareholder value in the evolving healthcare ecosystem [3].

Core Viewpoint - DarioHealth Corp. and GreenKey Health have formed a strategic partnership to address the $150 billion sleep apnea market, which affects over 29 million Americans, by providing an integrated chronic care solution that combines behavioral health, sleep, and cardiometabolic care [1][4]. Group 1: Collaboration Details - The collaboration combines Dario's AI-powered health solutions with GreenKey's sleep-first approach to obstructive sleep apnea management [2]. - The immediate focus is on engaging large payers and building a national network of service providers through targeted outreach and thought leadership [3]. - The partnership aims to secure payer contracts and enhance awareness through a multi-channel marketing plan targeting various healthcare plans and self-funded employers [2][3]. Group 2: Market Opportunity - The sleep apnea market is significant, with up to 80% of moderate to severe cases undiagnosed, leading to over $150 billion in annual costs due to related health issues [4]. - There is a growing demand for integrated solutions as payers shift towards value-based care, which the collaboration aims to fulfill [4]. Group 3: Expected Outcomes - The joint solution is designed to improve member health outcomes, reduce healthcare costs, and increase productivity through better sleep health and effective comorbidity management [6]. - The collaboration is expected to provide actionable data insights to continuously optimize program performance [6]. - By aligning behavioral health and sleep strategies with cardiometabolic interventions, the partnership offers a comprehensive approach to chronic care management [5].

CONCORD, Ontario, June 26, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) is excited to announce the official launch of PUR Rx, a next-generation digital health platform formed through a 50/50 joint venture with Synergy Health Rx Corp. Designed to transform how Canadians access prescribed therapies, PUR Rx merges digital innovation with trusted medical infrastructure to deliver patient-first care at scale. With the market for digital health in Canada expected to exceed CAD $4.7 billion by 2026 (S ...